Third Asset from Prevail Acquisition to be Shelved

Eli Lilly and Company (LLY) has discontinued the PROCEED Phase 1/2 trial (NCT05487599) for Gaucher Disease Type 1, which targeted the visceral symptoms. LY3884961 is a single-dose, AAV9-based gene therapy with a brand name and International Nonproprietary Name (INN) yet to be assigned, designed to deliver a functional GBA1 gene to restore glucocerebrosidase (GCase) activity. Lilly stated that the decision was based on internal portfolio criteria, not safety concerns, and did not release efficacy data. This follows the discontinuation of the Gaucher Disease Type 2 PROVIDE program in 2024 and the frontotemporal dementia program LY3884963 in February 2026, further weakening the clinical rationale for the Prevail acquisition.

Commercialization Hurdles Higher Than Market Anticipated

The Gaucher Disease market was approximately USD 1.7 billion in 2024, with chronic administration products establishing a stable revenue base. The standard of care includes Cerezyme and imiglucerase from Sanofi (SNY), and Cerdelga and eliglustat, and VPRIV and velaglucerase alfa from Takeda Pharmaceutical (TAK). The FDA approved Cerezyme on May 23, 1994, VPRIV on February 26, 2010, and Cerdelga on August 19, 2014, and all three products are commercially available. LY3884961 failed to reach the approval application or advisory committee (AdComm) review stage, and it could not overcome the burden of demonstrating clinical benefits beyond existing treatments, as well as cost and durability advantages.

FLT201 Poised to Lead Competitive Landscape

Spur Therapeutics' avigbagene parvec, FLT201, is an AAVS3-based gene therapy that delivers a stabilized GCase variant, and it has completed Phase 1/2 trials (GALILEO-1) for Gaucher Disease Type 1 and a Phase 2 meeting with the FDA. The company is advancing a registrational Phase 3 trial (GALILEO-3), putting it ahead of LY3884961 in development. Therefore, Lilly's withdrawal focuses both the clinical and regulatory validation burden for next-generation, single-dose gene therapies and the first-mover advantage on FLT201, rather than immediately disrupting the existing market for Cerezyme, VPRIV, and Cerdelga. From a patient perspective, the options for replacing repeat enzyme replacement therapy have decreased, while the value of late-stage clinical success for competitors has increased.

Remaining Value of USD 1.04 Billion Acquisition

Lilly completed the acquisition of Prevail Therapeutics in 2021, paying USD 22.50 per share, or USD 880 million in cash, and setting a conditional value right (CVR) of up to USD 160 million, linked to the first product approval. This was a USD 1.04 billion equity acquisition deal, not a royalty or milestone agreement. With the key Gaucher Disease and frontotemporal dementia programs being discontinued, the focus of the acquisition has narrowed to LY3884961 PROPEL Phase 1/2a (NCT04127578) for GBA1-mutant Parkinson's disease. This decision demonstrates that even large pharmaceutical companies re-evaluate patient selection, vector, sustained efficacy, and commercial viability in a step-by-step manner, even after acquiring early-stage gene therapy assets.